Certain content on our website is available for healthcare providers. Please confirm if you are an HCP to view full site content.


We’re Making Our Mark By Barely Leaving One

BIOVANCE helps move healing forward.

BIOVANCE is decellularized, dehydrated human amniotic membrane (DDHAM) derived from the placenta of a healthy, full-term pregnancy.


BIOVANCE is unique because it is prepared from the amnion—the part of the amniotic sac closest to the developing embryo. The amnion is excised from the chorion layer of the placenta, washed, and then sterilized so that it contains only what’s needed to support the body’s ability to heal.

The natural properties of the amniotic membrane support the growth and development of the baby. For 9 months, the amniotic membrane:

  • Forms the innermost lining of the placenta during gestation1
  • Is the tissue closest to the baby throughout development
  • Serves as a barrier to minimize risk of injury to the baby1-3

BIOVANCE brings the progenerative power of the amnion to tissue regeneration.1,2,4-7

BIOVANCE provides a foundation for the wound regeneration process. It is an intact, natural extracellular matrix (ECM) that acts as a scaffold for restoration of functional tissue. BIOVANCE contains key ECM proteins that allow for the migration of host cells to permeate the graft and promote tissue repair when applied to a wound.

BIOVANCE components

  • Collagen I, II, III, IV
  • Elastin
  • Glycosaminoglycans
  • Fibronectin
  • Laminin
  • Proteoglycans
Illustration of cross-section of pregnant woman’s abdomen with image of fetus within the placenta; callouts to amnion and chorion layers

See BIOVANCE Healing in Action

Watch a brief video animation that illustrates the mechanism of action of BIOVANCE.

Close-up of BIOVANCE held on two fingers with tweezer

Translucent grid pattern on the BIOVANCE allograft is evident on the wound until hydration occurs to allow view of the wound’s progress.

Easy to Use

BIOVANCE is easy to use, making it ideal for surgical and nonsurgical settings.

Easy to apply

  • No preparation needed – No thawing, rinsing, or soaking required prior to use
  • Flexible form – Conforms easily to irregular surfaces; can be wrapped around tendons or placed between adjacent tissues
  • Bidirectional orientation – Prevents the need for specific placement of BIOVANCE on the wound; can be applied with either side facing the wound
  • Adheres without sutures – Can be fastened by all surgical means if physician chooses to do so

Convenient storage

  • Ambient room-temperature storage in a clean, dry environment – No refrigeration necessary
  • 5-year shelf life – Eliminates the need for preordering

Immunologically Inert Tissue

BIOVANCE is immunologically inert tissue that has been minimally processed to maximize its natural benefits and safety.

  • BIOVANCE contains no antigens7, which further minimizes the risk of inflammatory response
  • Tissue derived from the amniotic membrane is cleaned and preserved without altering its native matrix architecture

Additional safety features

Tissue used in processing BIOVANCE:

  • Has been procured, processed, and tested in accordance with standards established by the American Association of Blood Banks (AABB) and the United States Food and Drug Administration (FDA)
  • Passed safety testing for cytotoxicity, hemolysis, irritation, endotoxins, and pyrogenicity
  • Utilizes a barcode tracking system for optimal safety monitoring and to enhance patient and practitioner confidence
BIOVANCE size chart

Available in 8 different sizes for application flexibility

1x2 cm
Product Code DHAM0012

2x2 cm
Product Code DHAM0022

2x3 cm
Product Code DHAM0023

2x4 cm
Product Code DHAM0024

3x3.5 cm
Product Code DHAM0035

4x4 cm
Product Code DHAM0044

5x5 cm
Product Code DHAM0055

6x6 cm
Product Code DHAM0066

Clinical Outcomes Gallery

BIOVANCE used in an excisional tissue transfer closure

Case characteristics:

  • 75-year-old female presented with chronic foot ulcer (>1 year) resulting from diabetic neuropathy
  • Initial treatment removed failed hardware and scar tissue from ulcer site
  • Treated with BIOVANCE allograft at each level during layered closure (capsule, subcutaneous/subcuticular), followed by offload with surgical shoe
  • Patient returned to extra depth shoe within 6 weeks with continued stability at incision site with viable tissue, no complications, and minimal scarring
ulcer pre-op

Ulcer Pre-Op

ulcer post-op

Ulcer Post-Op Day 47

BIOVANCE used in plantar hallux ulcers

Case characteristics:

  • 57-year-old male presented with diabetic plantar hallux ulcers (>1 year)
  • Initial treatment included wound-bed preparation with a high-powered saline debridement tool
  • BIOVANCE allografts were applied every 4 to 6 weeks until closure
  • Mature closure achieved following 2 applications to right foot and 3 applications to the left foot
Photo of ulcers on the big toe of both the left and right foot

BIOVANCE Application #1

Photo of toes with ulcers closed

Mature closure presented 1 month after decision to stop BIOVANCE

Connect With Celularity

For product questions, or ordering information, please contact us at customerservice@celularity.com or call us at 1-844-963-2273.

For medical inquiries, please contact us at medicalaffairs@celularity.com


  1. Fetterolf DE, Synder RJ. Scientific and clinical support for the use of dehydrated amniotic membrane in wound management. Wounds. 2012;24(10):299-307.
  2. Bhatia M, Pereira M, Rana H, et al. Mechanism of cell interaction and response on decellularized human amniotic membrane: implications in wound healing. Wounds. 2007;19(8):207-217.
  3. Arechavaleta-Velasco F, Marciano D, Díaz-Cueto L, Parry S. Matrix metalloproteinase-8 is expressed in human chorion during labor. Am J Obstet Gynecol. 2004;190(3):843-850.
  4. Faulk WP, Matthews R, Stevens PJ, et al. Human amnion as an adjunct in wound healing. Lancet. 1980;1(8179):1156-1158.
  5. Ganatra MA. Amniotic membrane in surgery. J Pak Med A. 2003;53(1):29-32.
  6. Portmann-Lanz CB, Ochsenbein-Kölble N, Marquardt K, et al. Manufacture of a cell-free amnion matrix scaffold that supports amnion cell outgrowth in vitro. Placenta. 2007;28(1):6-13.
  7. Niknejad H, Peirovl H, Jorjani M, et al. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater. 2008;15:88-99.